Genetic susceptibility to prostate cancer

被引:11
作者
Cussenot, O
Cancel-Tassin, G
机构
[1] Hop Tenon, Urol Serv, F-75020 Paris, France
[2] Univ Paris 07, CeRePP, F-75006 Paris, France
来源
M S-MEDECINE SCIENCES | 2004年 / 20卷 / 05期
关键词
D O I
10.1051/medsci/2004205562
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate cancer is the most frequent malignant tumor among men over 50 years old. Its incidence varies according to countries and ethnic group. Known risk factors are race and positive family history of the disease. Familial aggregation (at least 2 cases in the family) is observed in about 20% of cases and an hereditary form of prostate cancer in 5%. This proportion increases with younger age at diagnosis. Six putative loci are already identified but undoubtedly, others will be found in forthcoming studies. The genetic heterogeneity observed in hereditary prostate cancer reflects variety of origins of the studied families. In some families, agreggation of prostate cancer and other cancers suggests the involvement of common predisposing genes. In other familial and in sporadic cases, the genetic component should be polygenic: prostate cancer wouldn't result to segregation of a major gene mutations transmitted according to a monogenic inheritance, but rather to sharing of alleles at many loci, each contributing to a small increase in cancer risk. Indeed, several genetic polymorphism were associated with an increased risk of developing prostate cancer and could explain the variations of prostate cancer incidence observed between populations.
引用
收藏
页码:562 / 568
页数:7
相关论文
共 38 条
[1]   Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43 [J].
Berthon, P ;
Valeri, A ;
Cohen-Akenine, A ;
Drelon, E ;
Paiss, T ;
Wöhr, G ;
Latil, A ;
Millasseau, P ;
Mellah, I ;
Cohen, N ;
Blanché, H ;
Bellané-Chantelot, C ;
Demenais, F ;
Teillac, P ;
Le Duc, A ;
de Petriconi, R ;
Hautmann, R ;
Chumakov, I ;
Bachner, L ;
Maitland, NJ ;
Lidereau, R ;
Vogel, W ;
Fournier, G ;
Mangin, P ;
Cohen, D ;
Cussenot, O .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (06) :1416-1424
[2]  
Bosland M C, 2000, J Natl Cancer Inst Monogr, P39
[3]   Hereditary prostate cancer: Clinical aspects [J].
Bratt, O .
JOURNAL OF UROLOGY, 2002, 168 (03) :906-913
[4]   Association study of polymorphisms in the human estrogen ReceptorAlpha gene and prostate cancer risk [J].
Cancel-Tassin, G ;
Latil, A ;
Rousseau, F ;
Mangin, P ;
Bottius, E ;
Escary, JL ;
Berthon, P ;
Cussenot, O .
EUROPEAN UROLOGY, 2003, 44 (04) :487-490
[5]   PCAP is the major known prostate cancer predisposing locus in families from south and west Europe [J].
Cancel-Tassin, G ;
Latil, A ;
Valéri, A ;
Mangin, P ;
Fournier, G ;
Berthon, P ;
Cussenot, O .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2001, 9 (02) :135-142
[6]   MENDELIAN INHERITANCE OF FAMILIAL PROSTATE-CANCER [J].
CARTER, BS ;
BEATY, TH ;
STEINBERG, GD ;
CHILDS, B ;
WALSH, PC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) :3367-3371
[7]  
Chang BL, 2002, CANCER RES, V62, P1784
[8]   Vitamin D receptor polymorphisms as markers in prostate cancer [J].
Correa-Cerro, L ;
Berthon, P ;
Häussler, J ;
Bochum, S ;
Drelon, E ;
Mangin, P ;
Fournier, G ;
Paiss, T ;
Cussenot, O ;
Vogel, W .
HUMAN GENETICS, 1999, 105 (03) :281-287
[9]  
Cussenot O, 2001, Eur J Intern Med, V12, P11, DOI 10.1016/S0953-6205(00)00136-9
[10]  
CUSSENOT O, 2000, GENETIQUE UROLOGIE